Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 155

Similar articles for PubMed (Select 19825949)

1.

Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer.

Zhang D, LaFortune TA, Krishnamurthy S, Esteva FJ, Cristofanilli M, Liu P, Lucci A, Singh B, Hung MC, Hortobagyi GN, Ueno NT.

Clin Cancer Res. 2009 Nov 1;15(21):6639-48. doi: 10.1158/1078-0432.CCR-09-0951. Epub 2009 Oct 13.

2.
3.

Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients.

Yauch RL, Januario T, Eberhard DA, Cavet G, Zhu W, Fu L, Pham TQ, Soriano R, Stinson J, Seshagiri S, Modrusan Z, Lin CY, O'Neill V, Amler LC.

Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8686-98.

4.

MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model.

Bartholomeusz C, Oishi T, Saso H, Akar U, Liu P, Kondo K, Kazansky A, Krishnamurthy S, Lee J, Esteva FJ, Kigawa J, Ueno NT.

Mol Cancer Ther. 2012 Feb;11(2):360-9. doi: 10.1158/1535-7163.MCT-11-0400. Epub 2011 Dec 5.

5.

Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition.

Thomson S, Buck E, Petti F, Griffin G, Brown E, Ramnarine N, Iwata KK, Gibson N, Haley JD.

Cancer Res. 2005 Oct 15;65(20):9455-62.

6.

Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.

Xie M, He CS, Wei SH, Zhang L.

Eur J Cancer. 2013 Nov;49(16):3559-72. doi: 10.1016/j.ejca.2013.07.007. Epub 2013 Aug 2.

PMID:
23916913
7.

Human Mena+11a isoform serves as a marker of epithelial phenotype and sensitivity to epidermal growth factor receptor inhibition in human pancreatic cancer cell lines.

Pino MS, Balsamo M, Di Modugno F, Mottolese M, Alessio M, Melucci E, Milella M, McConkey DJ, Philippar U, Gertler FB, Natali PG, Nisticò P.

Clin Cancer Res. 2008 Aug 1;14(15):4943-50. doi: 10.1158/1078-0432.CCR-08-0436.

8.

Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.

Suda K, Tomizawa K, Fujii M, Murakami H, Osada H, Maehara Y, Yatabe Y, Sekido Y, Mitsudomi T.

J Thorac Oncol. 2011 Jul;6(7):1152-61. doi: 10.1097/JTO.0b013e318216ee52.

PMID:
21597390
9.
10.

Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors.

Buck E, Eyzaguirre A, Brown E, Petti F, McCormack S, Haley JD, Iwata KK, Gibson NW, Griffin G.

Mol Cancer Ther. 2006 Nov;5(11):2676-84.

11.

Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells.

Fuchs BC, Fujii T, Dorfman JD, Goodwin JM, Zhu AX, Lanuti M, Tanabe KK.

Cancer Res. 2008 Apr 1;68(7):2391-9. doi: 10.1158/0008-5472.CAN-07-2460.

12.

AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models.

Mu Z, Klinowska T, Dong X, Foster E, Womack C, Fernandez SV, Cristofanilli M.

J Exp Clin Cancer Res. 2014 May 30;33:47. doi: 10.1186/1756-9966-33-47.

13.

Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.

Guix M, Granja Nde M, Meszoely I, Adkins TB, Wieman BM, Frierson KE, Sanchez V, Sanders ME, Grau AM, Mayer IA, Pestano G, Shyr Y, Muthuswamy S, Calvo B, Krontiras H, Krop IE, Kelley MC, Arteaga CL.

J Clin Oncol. 2008 Feb 20;26(6):897-906. doi: 10.1200/JCO.2007.13.5939. Epub 2008 Jan 7.

14.

ZD6474, a dual tyrosine kinase inhibitor of EGFR and VEGFR-2, inhibits MAPK/ERK and AKT/PI3-K and induces apoptosis in breast cancer cells.

Sarkar S, Mazumdar A, Dash R, Sarkar D, Fisher PB, Mandal M.

Cancer Biol Ther. 2010 Apr 15;9(8):592-603. Epub 2010 Apr 4.

15.
17.

Silencing kinase-interacting stathmin gene enhances erlotinib sensitivity by inhibiting Ser¹⁰ p27 phosphorylation in epidermal growth factor receptor-expressing breast cancer.

Zhang D, Tari AM, Akar U, Arun BK, LaFortune TA, Nieves-Alicea R, Hortobagyi GN, Ueno NT.

Mol Cancer Ther. 2010 Nov;9(11):3090-9. doi: 10.1158/1535-7163.MCT-10-0362. Epub 2010 Nov 2.

18.

Peroxisome proliferator-activated receptor γ agonist efatutazone impairs transforming growth factor β2-induced motility of epidermal growth factor receptor tyrosine kinase inhibitor-resistant lung cancer cells.

Serizawa M, Murakami H, Watanabe M, Takahashi T, Yamamoto N, Koh Y.

Cancer Sci. 2014 Jun;105(6):683-9. doi: 10.1111/cas.12411. Epub 2014 May 10.

PMID:
24698130
19.

Insights into erlotinib action in pancreatic cancer cells using a combined experimental and mathematical approach.

Lange F, Rateitschak K, Kossow C, Wolkenhauer O, Jaster R.

World J Gastroenterol. 2012 Nov 21;18(43):6226-34. doi: 10.3748/wjg.v18.i43.6226.

20.

Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647.

Gendreau SB, Ventura R, Keast P, Laird AD, Yakes FM, Zhang W, Bentzien F, Cancilla B, Lutman J, Chu F, Jackman L, Shi Y, Yu P, Wang J, Aftab DT, Jaeger CT, Meyer SM, De Costa A, Engell K, Chen J, Martini JF, Joly AH.

Clin Cancer Res. 2007 Jun 15;13(12):3713-23.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk